3/6
10:59 am
oprx
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
Low
Report
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
3/6
10:11 am
oprx
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
Medium
Report
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
3/5
11:21 pm
oprx
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
3/5
10:17 pm
oprx
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
High
Report
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
3/5
06:50 pm
oprx
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/5
05:04 pm
oprx
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
High
Report
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
3/5
04:31 pm
oprx
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/5
04:01 pm
oprx
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
High
Report
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
3/5
01:36 am
oprx
OptimizeRx Q4 2025 Earnings Preview [Seeking Alpha]
Medium
Report
OptimizeRx Q4 2025 Earnings Preview [Seeking Alpha]
2/5
08:00 am
oprx
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
Medium
Report
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
1/8
02:21 pm
oprx
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades [Yahoo! Finance]
Low
Report
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades [Yahoo! Finance]
1/7
08:00 am
oprx
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
Medium
Report
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
12/23
10:05 am
oprx
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story [Seeking Alpha]
Low
Report
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story [Seeking Alpha]
12/17
07:26 am
oprx
OptimizeRx (NASDAQ:OPRX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
OptimizeRx (NASDAQ:OPRX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/17
05:38 am
oprx
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network [Yahoo! Finance]
Medium
Report
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network [Yahoo! Finance]
12/17
04:30 am
oprx
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
Medium
Report
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
12/14
01:26 am
oprx
Low
Report
12/10
08:36 am
oprx
Looking at the Narrative for OptimizeRx After Guidance Boost and Recurring Revenue Shift [Yahoo! Finance]
Low
Report
Looking at the Narrative for OptimizeRx After Guidance Boost and Recurring Revenue Shift [Yahoo! Finance]
12/10
04:10 am
oprx
OptimizeRx (NASDAQ:OPRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
OptimizeRx (NASDAQ:OPRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.